Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.41 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.38 |
| ▸ | CA12 | O43570 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
| ▸ | CA1 | P00915 | 1/20 | 0.30 |
| ▸ | CA2 | P00918 | 1/20 | 0.30 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7065470 | 0.80 | TSHR (0.42) | CA14CA12TSHRCA1CA2 | |
| SCHEMBL10012464 | 0.79 | SMN1; SMN2 (0.44) | SMN1; SMN2CA14CA12ALDH1A1KMT2A | |
| SCHEMBL13741176 | 0.77 | SMN1; SMN2 (0.42) | SMN1; SMN2CA14CA12ALDH1A1KMT2A | |
| SCHEMBL5864497 | 0.77 | TSHR (0.50) | SMN1; SMN2CA14CA12ALDH1A1KMT2A | |
| SCHEMBL866170 | 0.77 | TSHR (0.50) | SMN1; SMN2CA14CA12ALDH1A1KMT2A | |
| SCHEMBL13741138 | 0.77 | SMN1; SMN2 (0.42) | SMN1; SMN2CA14CA12ALDH1A1KMT2A | |
| SCHEMBL4446595 | 0.77 | SMN1; SMN2 (0.42) | SMN1; SMN2CA14CA12ALDH1A1KMT2A | |
| SCHEMBL10017663 | 0.77 | SMN1; SMN2 (0.42) | SMN1; SMN2CA14CA12ALDH1A1KMT2A | |
| SCHEMBL4676669 | 0.76 | ALDH1A1 (0.40) | SMN1; SMN2ALDH1A1KMT2ATSHRMEN1 | |
| SCHEMBL7361116 | 0.76 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1095935-B1 | 6-Hydroxy-5,6-dihydrouracils as herbicides | SUMITOMO CHEMICAL CO (JP) | 2008-12-17 | — | — | EP | disclosed |
| EP-1101761-B1 | Process for producing 3-phenyluracil compounds | SUMITOMO CHEMICAL CO (JP) | 2005-08-17 | — | — | EP | disclosed |
| US-20030216258-A1 | Condensed heterocylic compounds and herbicides containing them as active ingredients | SUMITOMO CHEMICAL COMPANY, LIMITED | 2003-11-20 | — | — | US | disclosed |
| US-6586368-B1 | Benzofuran derivatives | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2003-07-01 | — | — | US | disclosed |
| US-6410484-B1 | ACTIVE MATERIAL; CONTROLLING WEEDS | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2002-06-25 | — | — | US | disclosed |
| US-6339155-B1 | Process for producing 3-phenyluracil compounds | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2002-01-15 | — | — | US | disclosed |
| EP-1112268-A1 | CONDENSED HETEROCYCLIC COMPOUNDS AND HERBICIDES CONTAINING THEM | SUMITOMO CHEMICAL COMPANY LIMITED (JP) | 2001-07-04 | — | — | EP | disclosed |
| EP-1101761-A2 | Process for producing 3-phenyluracil compounds | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2001-05-23 | — | — | EP | disclosed |
| EP-1095935-A1 | 6-Hydroxy-5,6-dihydrouracils as herbicides | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2001-05-02 | — | — | EP | disclosed |
| WO-2000015633-A1 | CONDENSED HETEROCYLIC COMPOUNDS AND HERBICIDES CONTAINING THEM | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2000-03-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030216258-A1 | Condensed heterocylic compounds and herbicides containing them as active ingredients | CBR3, CBR1, HAAO | SMN1; SMN2 4622/4885CA14 2235/4885CA12 2025/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.